Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, RA Capital Nexus Fund III, L.P., holds the title of Director at SpyGlass Pharma, Inc..
On 2026-11-16, the insider transacted 1,000 shares.The shares were transacted at a weighted average price of $32.43 per share, resulting in a total market-relevant value of $32K.
RA Capital Nexus Fund III, L.P. (Director) bought $32K of $SGP
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.